Next Article in Journal
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
Next Article in Special Issue
Role and Redirection of IgE against Cancer
Previous Article in Journal / Special Issue
Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?
Antibodies 2012, 1(2), 149-171; doi:10.3390/antib1020149

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy

1,2,*  and 1,2
1 The Departments of Pediatrics, Human Oncology and Genetics and the UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53792, USA 2 Provenance Biopharmaceuticals Corp, Burlington, MA 01805, USA
* Author to whom correspondence should be addressed.
Received: 13 June 2012 / Revised: 26 June 2012 / Accepted: 26 June 2012 / Published: 4 July 2012
(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
View Full-Text   |   Download PDF [507 KB, uploaded 4 July 2012]   |   Browse Figures


Immunocytokines (ICs) are a class of molecules created by linking tumor-reactive monoclonal antibodies to cytokines that are able to activate immune cells. Tumor selective localization is provided by the ability of the mAb component to bind to molecules found on the tumor cell surface or molecules found selectively in the tumor microenvronment. In this way the cytokine component of the immunocytokine is selectively localized to sites of tumor and can activate immune cells with appropriate receptors for the cytokine. Immunocytokines have been made and tested by us, and others, using a variety of tumor-reactive mAbs linked to distinct cytokines. To date, the majority of clinical progress has been made with ICs that have linked human interleukin-2 (IL2) to a select number of tumor reactive mAbs that had already been in prior clinical testing as non-modified mAbs. Here we briefly review the background for the creation of ICs, summarize current clinical progress, emphasize mechanisms of action for ICs that are distinct from those of their constituent components, and present some directions for future development and testing.
Keywords: immunocytokine; ADCC; cancer; immunotherapy immunocytokine; ADCC; cancer; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Sondel, P.M.; Gillies, S.D. Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies 2012, 1, 149-171.

View more citation formats

Related Articles

Article Metrics


Cited By

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert